Bargetzi M, Baumann R, Cogliatti S, et al. Diagnosis and treatment of follicular lymphoma, an update. Swiss Med Wkly. 2018;148:w14635.
Dreyling M, Ghielmini M, Rule S, et al. Newly diagosed and relapsed follicular lymphoma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27 (supplement 5):v83-v90.
Gallagher CJ, Gregory WM, Jones AE, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986;10:1470-80.
Hübel K, Ghielmini M, Ladetto M, Gopal AK. Controversies in the treatment of follicular lymphoma. Hemasphere 2020 Feb; 4(1): e317.
Jacobson CA. Indolent lymphomas: Pushing the pace with novel agents. Hematology ASH Educ Program 2019, 1:279-286.
Luminari S, Ferrari A, Manni M, et al. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol 2017;36:689-696.
Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med, 2017;377:1331-1344.
Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010;28(29):4480-4.
Matasar MJ, Luminari S, Barr PM, et al. Follicular lymphoma: Recent and emerging therapies, treatment strategies, and remaining unmet needs. Oncologiste 2019 Nov; 24(11): e1236-e1250.
McNamara C, Montoto S, Eyre TA, et al. The investigation and management of follicular lymphoma. Br J Haematol 2020;191(3):363-381.
Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus Lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 2018;379:934-47.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). B-Cell Lymphomas. Version 4.2020-August 13, 2020.
Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutation in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015 Sep;16(9):1111-1122.
Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial. Lancet 2011;377(9759):42-51.
Trotman J, Barrington SF, Belada D, et al. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM: secondary analysis of a randomised, phase 3 trial. Lancet Oncol 2018; 19:1530-42.